https://peptide.zone/story/peptide-compounding-evidence-thin-hhs-policyPeptide Zoneen2026-11-02T05:00:00.000ZPeptide compounding evidence stays thin for six peptides in HHS policy https://peptide.zone/story/foundayo-sales-miss-forecasts-us-demandPeptide Zoneen2026-11-02T04:40:00.000ZFoundayo sales miss forecasts as Lilly says US demand more than tripled https://peptide.zone/story/bpc-157-anti-doping-rules-hhs-policyPeptide Zoneen2026-11-02T04:17:00.000ZBPC 157 anti doping rules stay in force after HHS compounding policy https://peptide.zone/story/torrent-semaglutide-brazil-launch-revenuePeptide Zoneen2026-11-02T03:42:00.000ZTorrent Pharma semaglutide Brazil launch eyed within nine months as Brazil sales rise 38 percent https://peptide.zone/story/hhs-peptide-compounding-policy-experts-splitPeptide Zoneen2026-11-01T04:51:00.000ZHHS peptide compounding policy splits pharmacists and pharmacologists